ARCH BIOPARTNERS INC (ARCH.CA) Stock Price & Overview
TSX-V:ARCH • CA03938C1041
The current stock price of ARCH.CA is 0.77 CAD. Today ARCH.CA is down by -3.75%. In the past month the price decreased by -1.28%. In the past year, price decreased by -58.82%.
ARCH.CA Key Statistics
- Market Cap
- 51.536M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.04
- Dividend Yield
- N/A
ARCH.CA Stock Performance
ARCH.CA Stock Chart
ARCH.CA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ARCH.CA. When comparing the yearly performance of all stocks, ARCH.CA is a bad performer in the overall market: 98.42% of all stocks are doing better.
ARCH.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARCH.CA. Both the profitability and financial health of ARCH.CA have multiple concerns.
ARCH.CA Earnings
ARCH.CA Forecast & Estimates
For the next year, analysts expect an EPS growth of -131.43% and a revenue growth -100% for ARCH.CA
ARCH.CA Groups
Sector & Classification
ARCH.CA Financial Highlights
Over the last trailing twelve months ARCH.CA reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 28.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10783.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ARCH.CA Ownership
ARCH.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| IOT | INNOVOTECH INC | N/A | 11.977M |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About ARCH.CA
Company Profile
Arch Biopartners, Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. The company is headquartered in Toronto, Ontario. The firm is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.
Company Info
IPO: 1996-10-09
ARCH BIOPARTNERS INC
545 King St W.
TORONTO ONTARIO M5V 1M1 CA
CEO: Richard Muruve
Employees: 0
Phone: 16474287031
ARCH BIOPARTNERS INC / ARCH.CA FAQ
What does ARCH do?
Arch Biopartners, Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. The company is headquartered in Toronto, Ontario. The firm is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.
Can you provide the latest stock price for ARCH BIOPARTNERS INC?
The current stock price of ARCH.CA is 0.77 CAD. The price decreased by -3.75% in the last trading session.
Does ARCH BIOPARTNERS INC pay dividends?
ARCH.CA does not pay a dividend.
How is the ChartMill rating for ARCH BIOPARTNERS INC?
ARCH.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does ARCH BIOPARTNERS INC belong to?
ARCH BIOPARTNERS INC (ARCH.CA) operates in the Health Care sector and the Life Sciences Tools & Services industry.
How is the valuation of ARCH BIOPARTNERS INC (ARCH.CA) based on its PE ratio?
ARCH BIOPARTNERS INC (ARCH.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.04).